Endurant Capital Management’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Endurant Capital Management’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-243,795	Closed	-$322K	–	81
2022 Q1	$322K	Sell	243,795 -116,283	-32%	-$189K	0.08%	62
2021 Q4	$940K	Sell	360,078 -772,445	-68%	-$2.33M	0.23%	61
2021 Q3	$3.52M	Sell	1,132,523 -997,186	-47%	-$3.33M	0.8%	31
2021 Q2	$7.92M	Sell	2,129,709 -33,809	-2%	-$113K	2.18%	13
2021 Q1	$7.49M	Buy	+2,163,518	New	+$8.78M	1.95%	22

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Endurant Capital Management's PHAS Position: Q2 2022 in Review

Endurant Capital Management sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q2 2022, closing a stake of 243,795 shares — an estimated $322K sold.

Endurant Capital Management first reported a position in PHAS in Q1 2021 and held it in 5 quarters. The position peaked at $7.92M in Q2 2021. 49 funds tracked by Wall St. Rank hold PHAS as of Q2 2022.

Endurant Capital Management reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Endurant Capital Management sold 243,795 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $322K.
Endurant Capital Management first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
Endurant Capital Management's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $7.92M in Q2 2021.
49 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Endurant Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.